Posted on

Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin

Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin

Vancouver, British Columbia, Canada – January 21, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has optimized its recombinant production system (the “System”), successfully testing its proof of concept for the biosynthesis of psilocybin suitable for use in future scale-up and has filed a patent application with the United States Patent and Trademark Office (“USPTO”) titled “Production of Psychedelic Compounds” for protection of its novel psilocybin production system. Psilocybin is a psychedelic compound that is showing enormous promise in treating addiction and depression.

The Company’s team of scientists at Vocan have constructed optimized DNA sequences that can produce enzymes replicating the biosynthetic pathway used by Psilocybe mushrooms. This allows bacteria to become factories for psilocybin production. Under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, Vocan CEO, Vocan scientists have used DNA modeling to improve and optimize design and produce unique DNA sequences that improve the efficiency and expression of these enzymes, allowing for rapid and cost-effective psilocybin production.
Currently, most companies use chemically synthesized psilocybin as the only available cGMP compliant product that is available in large volumes. The chemical process carries significant costs and is less efficient when compared to a biologically derived psilocybin. Vocan’s biosynthetic process retains the stereochemistry of the natural psilocybin molecules found in hallucinogenic mushrooms, which are known to have a more positive effect than the chemically synthetized counterpart. However, these tiny mushrooms are not an efficient source of psilocybin since the amount produced is quite small and variable.
Vocan’s successful production system engineers bacteria incorporating optimized biosynthetic genes from the Psilocybe mushroom and other species and enables the bacteria to act as a biological factory and synthesize psilocybin.

Additionally, the Company’s team of scientists hypothesise that by using a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds, there is potential to produce other known and novel analogs of psilocybin and related psychedelics. The analog compounds may potentially be more effective, targeted, and safer than the natural compounds.

The patent application entitled “Production of Psychedelic Compounds” includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients. Vocan’s method of psilocybin production will provide more affordable access to organizations looking to acquire cGMP API grade psilocybin. Vocan’s psilocybin production method utilizes the well-established industrial process of fermentation and thus can be scaled up while consistently producing a high-quality cGMP product.

“I am very pleased to say that we are fulfilling our promise to our shareholders and to the medical and research sectors, in general, that we have successfully produced biosynthesized psilocybin. Our team of scientists continue to achieve significant and astounding scientific milestones. Our goal is to play a significant role in furthering mental health research and the benefits of psychedelic medicines, and our cost-effective psychedelic compounds will go a long way towards allowing otherwise cost prohibitive medicines to be widely used,” Stated Dr. Hancock, Chairman of the Company, and CEO of Vocan. “This successful proof of concept for development and production of cost effective and stereochemically sound psilocybin puts Core One in a very unique position. It not only potentially positions the Company as first to market with a biosynthetic psychedelic, it positions us to become market-leaders with regards to cost efficiency, as well.

ABOUT CORE ONE LABS INC.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.
Joel Shacker
Chief Executive Officer

FOR FURTHER INFORMATION:
Email: info@core1labs.com
Telephone: 1-866-347-5058

FOLLOW US:
Website: https://core1labs.com/
Twitter: https://twitter.com/Coreonelabs
Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/
LinkedIn: https://www.linkedin.com/company/core-one-labs
Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Lexston Announces the Launch of a Psychedelic Mushrooms Genetic Identification Test

Lexston Announces the Launch of a Psychedelic Mushrooms Genetic Identification Test

Vancouver, British Columbia, January 24, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE: LEXT) (OTCQB: LEXTF) is pleased to announce that the Company’s wholly owned subsidiary, Egret Bioscience Ltd. (“Egret”) has developed and validated a targeted genetic barcode consisting of eight Single Nucleotide Polymorphism (“SNP”) for psychedelic mushroom genetic identification (“Egret Psilocybe Assay”). Egret has previously developed and published similar genetic identification tests for the Cannabis Industry (https://t.co/rh1VJ5cf0a) and have been offering this service to licensed producers through its affiliated licensed lab, Zenalytic Laboratories Ltd. In early January, the Controlled Substances Directorate of Health Canada amended their regulations to allow practitioners to prescribe restricted drugs, such as psilocybin and psilocin through the Special Access Program (“SAP”) for patient with treatment resistant depression and other debilitating illnesses that have failed to respond to conventional treatments. As with other restricted drugs, Health Canada has mandated a stringent quality control and compliance routine testing for every batch destined for the SAP. One of the key requirements put in place by the regulator is the requirement for a genetic identity test. “Our team has been steadfast at work to develop and implement validated state-of-the-art methods for genetic identification of psychedelic mushrooms. Our assay provides the first of its kind Psilocybe genetic barcode, a rapid and efficient diagnostic test able to provide individual genetic strain identification and differentiate strains from the main groups of Psilocybe mushrooms, in particular P. cubensis, P. tampanensis and P. mexicana (P. galindoi). This traceability and authentication tool will be paramount in establishing best practice for the psychedelic industry.” Stated Jag Bal, CEO and Director of Lexston.

Lexston Phylogenetic tree

Phylogenetic tree showing the relationship between 84 psychedelic mushroom samples from which the Egret genetic barcode was developed. Reproduced from data made available by McKernan and colleagues (2021; https://doi.org/10.12688/f1000research.55301.2). Of particular note, the more potent P. cubensis accessions such as P. Envy cluster closely to the P. azurescens, P. tampanensis and P. mexicana accessions.

For more information and to subscribe to the Company’s mailing list, please visit https://lexston.ca/contact/ 

About Lexston Life Sciences Corp.

Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.

On Behalf of the Board of Directors

LEXSTON LIFE SCIENCES CORP.

Jagdip Bal
Chief Executive Officer
Telephone: (604) 928-8913

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

929 Mainland Street Vancouver, BC V6B 1S3

Phone: (604) 928-8913

Fax: (604) 628-0129

Email: admin@lexston.net

Website: www.lexston.ca

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Posted on

Bill filed in Kansas to legalize psilocybin possession and cultivation

Controversial Kansas Lawmaker Files Bill To Legalize Psilocybin Possession And Cultivation

A Kansas legislator filed a bill to legalize the possession of up to 50 grams of psilocybin or psilocin, as well as the cultivation of psilocybin mushrooms. Possessing 50-100 grams would be considered a civil offense with a fine of up to $250. Possessing over 100 grams would be a misdemeanor with a fine of up to $500 and up to one month in jail.

PDF of article

Posted on

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD).

More than 320 million people globally suffer with major depressive disorder (MDD)[i], the leading cause of disability worldwide and one of the fastest growing mental health illnesses[ii]. About a third of these patients – 100 million people – aren’t helped by existing therapies and suffer with TRD[iii].

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges, including TRD. It combines the pharmacological effects of a synthesised version of psilocybin, a psychoactive substance that is an active ingredient in some species of mushrooms, with psychological support[iv].

The survey of 259 Sermo member physicians, sponsored by COMPASS, was conducted in November 2021 and completed by participants from the US, the UK, France, Italy, Denmark, Spain and the Netherlands. Doctors were asked their views on the future of psychiatric therapy and the potential role of psilocybin therapy.

Key survey findings:

  • 66% of doctors surveyed believe psilocybin therapy has potential benefit for patients with TRD
  • 50% would prescribe psilocybin therapy, if it was approved; 32% are undecided
  • The greatest potential advantages to psilocybin treatment are believed to be: improved efficacy in treatment-resistant conditions (30%), rapid onset of action (26%), and different mechanism of action from existing therapies (19%)
  • The greatest potential barriers to treatment were cited as: needing a dedicated space for six to eight hours (28%), lack of trained therapists in a new model of psychological support (21%), and office infrastructure (15%)
  • Opinions on the optimal setting for psilocybin administration varied by region: 50% of European respondents said hospital; 42% of US respondents said specialised network of centres
  • Physicians also noted the need to educate healthcare professionals on the potential benefits of psilocybin therapy and on how to incorporate the therapy into their practice, if approved

“Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed,” said Murali Doraiswamy MBBS, FRCP, Professor of Psychiatry and Behavioural Sciences at Duke University School of Medicine, and an advisor to Sermo.

Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: “These findings underline the fact that physicians need more options in helping patients suffering with treatment-resistant depression. COMPASS is developing COMP360 psilocybin therapy through a rigorous programme of research in the hope that we can offer just such an option. It’s very encouraging to see that so many doctors see the potential that psilocybin could have and these insights will help us to understand how to introduce COMP360 psilocybin, with psychological support, into medical systems, if approved.”

-Ends-

Survey methodology   

The survey was designed to assess attitudes towards the use of psilocybin therapy in general, in psychiatry. The survey was conducted online via Sermo’s RealTime platform and the random sample of physicians received compensation for their time and expertise. Survey limitations include sampling bias, inability to deduce causality from opinion polls, confounding variables not measured, and other factors.

About COMPASS Pathways       

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, the safety or efficacy of psilocybin therapy, including COMP360, as a treatment for depression, COMPASS’s business strategy and goals, including its ability to launch and commercialise products, COMPASS’s expectations for the timing of its pivotal phase III programme and the potential for that or other trials to support regulatory filings and approvals, COMPASS’s ability to continue to advance its research or develop plans to bring its product candidates to patients, including  COMP360, clinicians’ perceptions of the potential advantages and efficacy of COMP360 in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating, and COMPASS’s expectations regarding the benefits of psilocybin therapy and the effectiveness of its executive team. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

About Sermo

Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com.

Enquiries

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

[i] WHO (2017). Depression and Other Common Mental Disorders Global Health Estimates [Online]. Available at: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf [Accessed 21 October 2021]

[ii] WHO (2012). Depression: A Global Crisis [Online]. Available at: https://www.who.int/mental_health/management/depression/wfmh_paper_depression_wmhd_2012.pdf [Accessed 21 October 2021]

[iii] Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Preference and Adherence. 2012; 6: 369–388

[iv] Ross et al, 2016; Griffiths et al, 2016; Carhart-Harris et al, 2016

Posted on

Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD

Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD

VANCOUVER, BRITISH COLUMBIA, Jan. 11, 2021 – A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, reports that nearly two thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psychedelic medicine (i.e. ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. 

According to the survey, conducted online in December, 2021 among 953 U.S. adults who suffer from anxiety/depression/PTSD, nearly two-thirds (63%) of Americans who have used prescription medications to treat anxiety/depression/PTSD say that while the medication helped, they still experienced residual feelings of anxiety, depression or PTSD. Furthermore, 18% say that the medication did not improve their condition/made it worse.

“We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” said Matt Stang, co-founder and CEO of Delic. “This promising family of new medicines has the potential to be more effective than traditional medicines with minimal side effects, giving people their best selves back. Our country’s mental health crisis not only impacts public health, but also the economy–each year, untreated mental illness costs the U.S. up to $300 billion in lost productivity.”

According to the study, 83% of Americans experiencing anxiety, depression or PTSD would be open to pursuing alternative treatments proven to be more effective than prescription medication with fewer side effects. Among those who suffer from anxiety/depression/PTSD, many would be open to using the following substances which have been identified as potential alternative treatments for those seeking to address their mental health conditions:

  • Ketamine: 66% would be open to pursuing treatment using ketamine to treat anxiety, depression or PTSD if it was proven more effective than prescription medication with fewer side effects.
  • Psilocybin: 62% said they would be open to pursuing treatment using psilocybin prescribed by a physician to address their anxiety, depression or PTSD if it was proven more effective than prescription medication with fewer side effects.
  • MDMA: 56% would be open to pursuing treatment using MDMA prescribed by a physician to treat their anxiety, depression or PTSD if it was proven more effective than prescription medication with fewer side effects.

Survey Method

This survey was conducted online within the United States by The Harris Poll on behalf of Delic from December 6 – 8, 2021 among 2,037 adults ages 18 and older, among whom 953 suffer from anxiety/depression/PTSD. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact delic@mattio.com.

About The Harris Poll

The Harris Poll is one of the longest running surveys in the U.S., tracking public opinion, motivations and social sentiment since 1963. It is now part of Harris Insights & Analytics, a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. We work with clients in three primary areas: building twenty first century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward Looking Statements

This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning a national consumer survey conducted by The Harris Poll. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those exp “We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” said Matt Stang, co-founder and CEO of Delic ressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed September 23, 2019, which is available under the Company’s SEDAR profile at www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Posted on

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

Company identifies unique two-part extraction and transdermal delivery process

VANCOUVER, BC (GLOBE NEWSWIRE – January 18, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components.

The extraction process uses a highly viscous material to isolate key components of psychedelic mushrooms and dissolves the psilocybin into a molecular solution. Using the same energy, the active ingredients are then repelled into the skin when applied topically. Due to the skin’s highly permeable membrane, Optimi’s solution has a natural time-release effect, which allows for a more sustained release into the body and provides a patient with the ability to experience the desired outcome for longer periods of time.

As Chief Science Office Justin Kirkland explains, “The most novel part of this process is that we are performing two very different functions with a single unique component. This component works much like the attraction and repulsion properties of a magnet with a North and South end. We leverage this energy to perform two functions. First, the attraction energy will extract psilocybin out of the mushroom. Second, when this same material is applied to the skin, it will advance the drug through the skin and into the bloodstream.”

Containing all GRAS certified ingredients, this solution can then be loaded into our proprietary drug delivery system for direct passage through the skin into the bloodstream. Transdermal application avoids the first pass metabolism and degradation of psilocybin by the liver that occurs with traditional oral drug delivery, which increases bioavailability of the active ingredient.

In the continued effort to champion all things natural, Optimi’s delivery system has been designed to require no additional shuttling agents. Instead, the repulsion technology steadily pushes the active ingredient through the various layers of the skin, and treatment begins almost immediately upon application. This new process will help to reduce costs and resources while providing patients with a superior product.

Optimi is focused on providing patients with a safe, consistent, and pure psychedelic product. Developing multiple extraction and delivery system methods is part of the Company’s commitment to ensuring patients have options when deciding their treatment.

“This unique chemistry provides improved bioavailability of Optimi’s psilocybin,” said Optimi CEO Bill Ciprick. “Our IP is evidence of Optimi Health’s continued commitment to sustainability by using green chemistry to achieve both the extraction and topical formulations.” Mr. Ciprick adds, “As patient access remains the focal point among regulators, lobbyists and Companies such as our own, we look forward to being able to provide our variety of therapies to those in need.”

On Behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.Search

CATEGORIES

OPTIMI HEALTH SUBMITS NATURAL PSILOCYBIN COMBINED DRUG DELIVERY AND EXTRACTION FORMULATIONS FOR PROVISIONAL PATENT

18 JANUARY 2022

OPTIMI HEALTH PROVIDES DEALER LICENSE UPDATE AND COMMENTS ON HEALTH CANADA’S AMENDMENTS TO THE SPECIAL ACCESS PROGRAM (SAP)

5 JANUARY 2022

OPTIMI HEALTH RECEIVES DEALERS LICENSE INSPECTION AND INTRODUCES QUALITY ASSURANCE DEPARTMENT

21 DECEMBER 2021

OPTIMI HEALTH REQUESTS FINAL INSPECTION FOR DEALER’S LICENSE

7 DECEMBER 2021

OPTIMI HEALTH ENGAGES EXPERT MANAGEMENT CONSULTANCY TO DRIVE CORPORATE VISIBILITY

3 NOVEMBER 2021

OPTIMI HEALTH APPOINTS PRINCIPAL INVESTIGATOR FOR CLINICAL DOSING STUDY

19 OCTOBER 2021Email

Posted on

Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State

Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State

Red Light Holland (TRIP) is collaborating with an advocacy group called the Psychedelic Medicine Alliance Washington to promote a bill that would legalize guided psilocybin sessions in Washington State. The company has hired a lobbyist with experience in cannabis regulation and is launching a social media campaign and educational events to raise awareness about the benefits of psilocybin.

Red Light Holland Corp.

PDF of article

Posted on

Microdosing eases depression

Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

In a preclinical animal model, Wesana Health (WESA) found that a single high dose of psilocybin rapidly improved depressive behaviours for 14 days. A regimen of psilocybin microdoses and CBD was able to sustain the results and reduced depressive behaviours by an additional 64%.

Let’s keep the microdosing evidence coming!

PDF of article

Posted on

Telescope Files Patent Cooperation Treaty Application on Scalable Psilocybin and Tryptamine Synthesis

Telescope Files Patent Cooperation Treaty Application on Scalable Psilocybin and Tryptamine Synthesis

Vancouver, BC — January 17, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI) announces that it has filed a Patent Cooperation Treaty (“PCT”) patent application for its scalable manufacturing methods to produce psilocybin and related tryptamine compounds. This application claims the priority date of a preceding provisional application filed with the United States Patent and Trade Office on December 31, 2020.

This PCT filing covers novel synthetic routes for the production of psilocybin and psilocin along with their precursors, analogs, and derivatives. These molecules belong to the tryptamine class of compounds that has been gaining momentum in the psychedelic medicine space in recent years. The processes outlined in this patent application are positioned to enable scalable manufacturing because they require fewer synthetic steps than current methods, utilize cost effective and readily available starting materials, and leverage chemical manufacturing processes that are already standard practice in the pharmaceutical industry. Telescope’s synthetic methods are therefore well-poised for compatibility with the standards of current Good Manufacturing Practices (cGMP) ultimately required for pharmaceutical deployment.

Jason Hein, CEO of Telescope, noted, “the demand for pharmaceutical-grade psilocybin and psychedelic tryptamines is rising. We are seeing increased numbers of trials and studies advancing these compounds along the drug development pipeline, but there has been relatively little focus on how these molecules will be reliably produced at a large scale. Telescope’s patent represents a significant milestone in addressing the impending manufacturing bottleneck.”

The synthetic processes described in the PCT application are not limited to the production of psilocybin, but enable access to a wide variety of tryptamines and can be easily adapted to produce specific derivatives. Derivatives are currently being explored by drug development companies seeking to tune the predictability, potency, or pharmacokinetic profiles of psychedelic therapeutics. Telescope’s intellectual property portfolio is therefore flexible and amenable to changing demands as different molecules are targeted throughout pharmaceutical development in the psychedelic space. Indeed, while developing proprietary synthesis processes, Telescope has discovered new molecules (Novel Chemical Entities; “NCEs“) that may become candidates for preclinical development. These NCEs are also captured within the PCT application.

“We’re very pleased with Telescope’s research results this year,” added Hein. “The Company is set up very well to continue developing our intellectual property portfolio and bringing our discoveries closer to deployment.”

About Telescope

Telescope is a chemical technology company developing scalable, widely deployable synthetic processes to manufacture pharmaceuticals for the treatment of mental health. The Company develops new enabling technology to achieve these goals, including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Research and development efforts are currently focused on medicines from the under-utilized tryptamine class of compounds, leveraging innovative process chemistry both to optimize synthetic procedures and access novel molecules. Our aim is to bring modern chemical solutions to meet the most serious challenges in human health. 

On behalf of the Board,

Telescope Innovations Corp.

Jason Hein, Chief Executive Officer

E: jason@telescopeinn.com 

Forward-Looking Information

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the prospectus filed by the Company and available at www.sedar.com.

Forward-looking statements in this document include expectations surrounding the patent filing process and the timing thereof, anticipated trends in the demand for psychedelic medical treatments and the ability of the intellectual property portfolio of the Company to respond to this demand, and all other statements that are not statements of historical fact.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic, including the risk that the Company be deemed a non-essential business and asked to temporarily cease operations; general economic conditions; adverse industry events; future legislative and regulatory developments involving psilocybin; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the psilocybin industry in Canada and generally; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.

These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.